MA-ASTADIA
23.3.2021 15:02:11 CET | Business Wire | Press release
In today’s environment, many organizations have a “Cloud First” strategy for deploying business applications. Since most of the important business applications reside on mainframes, moving these applications and databases to any Cloud platform requires expert skills and technology.
The combination of Astadia’s Replatforming solutions, plus the Anubex Refactoring capabilities, offers a complete mainframe migration RoadMap. Astadia now offers all solution sets required to migrate from any IBM Z Series, or Unisys ClearPath platform, to the Cloud platform of their choosing.
“This is an exciting time to be in the Mainframe Migration business. The rapidly shrinking pool of people with mainframe software and hardware skills has given a new sense of urgency to IT buyers. The shortage of these critical skills is exacerbated by the COVID-19 Pandemic,” said Scott G. Silk, Chairman and CEO of Astadia.
“With this wave of Cloud computing, organizations are rapidly moving their applications and databases from mainframes. The Cloud enables incredible software innovation and developer productivity, access to AI and Predictive Analytics, while only charging the client for the resources they consume,” said Mr. Silk.
“Combining the forces of Astadia and Anubex leads to a unique combination of sales and delivery power with an exceptional portfolio of solutions for the migration market. This team is ready to accompany the largest organizations on their journey to the Cloud and becomes an important player in the top tier of mainframe migration companies,” said Louis Heymans, Managing Director of Anubex.
The acquisition of Anubex by Astadia allows the Anubex R&D team to continue to focus on extending their portfolio of products (CodeTurn, DataTurn, TestMatch and DataMatch) to automate refactoring and testing of legacy systems. The development of these products started well over 20 years ago, and today includes legacy technologies such as Assembler, COBOL, IDMS and Natural ADABAS that can be migrated to, among others, Java or C# in combination with all the leading SQL-databases – with the resulting applications ready for deployment in the (public) Cloud. These solutions using a Cloud-based “Migration Factory” model will be available to Astadia partners and clients worldwide.
For more details, take advantage of Astadia’s FREE Mainframe-to-Cloud Modernization Guide series, where we assist our clients as they plan and move into a safe and secure, high performance, cloud environment. This series covers IBM (NYSE:IBM) and UNISYS (NYSE:UIS) mainframes, and all popular target Cloud Platforms.
In these Mainframe-to-Cloud Migration Guides , readers will explore 20 pages of:
- Why migrate mainframe applications & databases to the Cloud?
- The challenges associated with mainframe modernization
- Detailed diagrams of mainframe software mappings to Cloud Platforms
- Programming languages & database translation tables
The Mainframe-to-Cloud Guide series is FREE , and may be downloaded.
Click on this link to view the Astadia Mainframe-to-Cloud Modernization Guide Series.
For more information visit http://www.astadia.com and follow Astadia at @AstadiaInc , Facebook/AstadiaInc , LinkedIn/Astadia
About Anubex
Anubex is an industry leader providing core software solutions, know-how, and support for complex mainframe-to-cloud migration and modernization projects.
With over 25 years of experience, demonstrated solutions and high-performing software tools, we help enterprises and government organizations boost their innovation capacity, competitiveness and agility by accelerating their digital transformation.
We are migration specialists, independent of the legacy or target technology stack. Our core competence lies in the know-how, the unique software solutions, and the extensive experience in how complex migration projects should be undertaken: what the stages and steps are, how the project should be structured, what the typical pitfalls and risks are, and how processes should be automated.
Our automated conversion and testing tools , combined with an innovative migration methodology , enable our team to support complex modernization projects and be one of the most competitive and reliable migration companies in the world.
Contacts / Headquarters
www.anubex.com
Anubex HQ
Anubex NV
Veldkant 13
2550 Kontich
Belgium
+32 3 450 42 50
migrations@anubex.com
About Astadia
Astadia is the market leading mainframe modernization consulting and systems integration boutique. A worldwide IT consulting firm, we specialize in moving IBM and Unisys mainframe applications and databases to distributed and cloud platforms. In fact, we were recently named Microsoft’s Mainframe-to-Azure partner of the year. Clients select Astadia for the following reasons: mainframe to cloud market focus, 28 years of mainframe experience, and hybrid READI methodology. Upon project completion, customers often select Astadia to manage their cloud environment as well. We have successfully completed over 200 mainframe modernization projects and are recognized industrywide as the mainframe to cloud experts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom